(An Autonomous Body Recognized by Ministry of Commerce & Industry, Government of India)
OSE reports overall survival success in Phase II PDAC vaccine trial
OSE Immunotherapeutics’ Phase II TEDOPaM trial has shown promising results for its neoepitope-based cancer vaccine, Tedopi (OSE2101), in pancreatic ductal adenocarcinoma (PDAC). The study met its overall survival (OS) goal, demonstrating positive outcomes with minimal toxicity, though full results have not yet been released.
The randomized, non-comparative trial (NCT03806309) evaluated Tedopi in combination with Opdivo (nivolumab) followed by chemotherapy (FOLFIRI) against FOLFIRI alone as maintenance therapy. Conducted across multiple centers in France, the study enrolled 107 patients with HLA-A2 positive PDAC who had no disease progression after eight cycles of FOLFIRINOX induction chemotherapy.
Pancreatic cancer remains highly aggressive, with an estimated 67,440 new cases and nearly 52,000 deaths expected in 2025. Tedopi’s market potential is projected to reach $95 million by 2029 and $334 million by 2031. Further analysis will be needed to assess long-term survival benefits, but these findings highlight the need for improved PDAC treatments.
18-03-2025